Ketamine: A Controversial Drug for Neonates

Seminars in Perinatology

Volumn 31, Issue 5, 2007, Pages 303-308

  Bhutta, Adnan T ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

excitotoxicity; glutamate receptors; ketamine; neurotoxicity; NMDA

Indexed keywords

BENZODIAZEPINE; HYPERTENSIVE AGENT; KETAMINE; MIDAZOLAM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; OPIATE; REMIFENTANIL;

ANESTHESIA; BRAIN MATURATION; CELL DEATH; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; EXCITOTOXICITY; HUMAN; INTRACRANIAL HYPERTENSION; LARYNX SPASM; NEWBORN PERIOD; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESPIRATION DEPRESSION; REVIEW; SEDATION; VOMITING;

ANESTHETICS, DISSOCIATIVE; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INFANT, NEWBORN; KETAMINE; PAIN; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 34648837429     PISSN: 01460005     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semperi.2007.07.005     Document Type: Review

References (97)

1. Woodbridge P.D. Changing concepts concerning depth of anesthesia. Anesthesiology 18 (1957) 536-550
2. Ball C., and Westhorpe R. Intravenous induction agents: ketamine. Anaesth Intensive Care 30 (2002) 115
3. Corssen G., and Domino E.F. Dissociative anesthesia: further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth Analg 45 (1966) 29-40
4. Greifenstein F., Devault M., Yoshitake J., et al. A study of a 1-aryl cyclo hexyl amine for anesthesia. Anesth Analg 37 (1958) 283-294
5. McCarthy D.A., Chen G., Kaump D.H., et al. General Anesthetic And Other Pharmacological Properties Of 2-(O-Chlorophenyl)-2-Methylamino Cyclohexanone Hcl (Ci-58l). J New Drugs 28 (1965) 21-33
6. Domino E.F., Chodoff P., and Corssen G. Pharmacologic Effects Of Ci-581. A new dissociative anesthetic. Man Clin Pharmacol Ther 6 (1965) 279-291
7. Lin C., and Durieux M.E. Ketamine and kids: an update. Paediatr Anaesth 15 (2005) 91-97
8. Restall J., Tully A.M., Ward P.J., et al. Total intravenous anaesthesia for military surgery. A technique using ketamine, midazolam and vecuronium. Anaesthesia 43 (1988) 46-49
9. Wright M. Pharmacologic effects of ketamine and its use in veterinary medicine. J Am Vet Med Assoc 180 (1982) 1462-1471
10. Jansen K.L. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs 32 (2000) 419-433
11. Jansen K.L., and Darracot-Cankovic R. The nonmedical use of ketamine, part two: a review of problem use and dependence. J Psychoactive Drugs 33 (2001) 151-158
12. Reich D.L., and Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 36 (1989) 186-197
13. Cohen M.L., Chan S.L., Way W.L., et al. Distribution in the brain and metabolism of ketamine in the rat after intravenous administration. Anesthesiology 39 (1973) 370-376
14. Dayton P.G., Stiller R.L., Cook D.R., et al. The binding of ketamine to plasma proteins: emphasis on human plasma. Eur J Clin Pharmacol 24 (1983) 825-831
15. Kohrs R., and Durieux M.E. Ketamine: teaching an old drug new tricks. Anesth Analg 87 (1998) 1186-1193
16. Annetta M.G., Iemma D., Garisto C., et al. Ketamine: new indications for an old drug. Curr Drug Targets 6 (2005) 789-794
17. Grant I.S., Nimmo W.S., McNicol L.R., et al. Ketamine disposition in children and adults. Br J Anaesth 55 (1983) 1107-1111
18. Malinovsky J.M., Servin F., Cozian A., et al. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth 77 (1996) 203-207
19. Cederholm I., Bengtsson M., Bjorkman S., et al. Long term high dose morphine, ketamine and midazolam infusion in a child with burns. Br J Clin Pharmacol 30 (1990) 901-905
20. Saarenmaa E., Neuvonen P.J., Huttunen P., et al. Ketamine for procedural pain relief in newborn infants. Arch Dis Child Fetal Neonatal Ed 85 (2001) F53-F56
21. Himmelseher S., and Durieux M.E. Revising a dogma: ketamine for patients with neurological injury?. Anesth Analg 101 (2005) 524-534
22. Koinig H., and Marhofer P. S(+)-ketamine in paediatric anaesthesia. Paediatr Anaesth 13 (2003) 185-187
23. Pees C., Haas N.A., Ewert P., et al. Comparison of analgesic/sedative effect of racemic ketamine and S(+)-ketamine during cardiac catheterization in newborns and children. Pediatr Cardiol 24 (2003) 424-429
24. Breier A., Malhotra A.K., Pinals D.A., et al. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154 (1997) 805-811
25. Duncan G.E., Miyamoto S., Leipzig J.N., et al. Comparison of brain metabolic activity patterns induced by ketamine. MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843 (1999) 171-183
26. Duncan G.E., Miyamoto S., Leipzig J.N., et al. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 293 (2000) 8-14
27. Duncan G.E., Moy S.S., Knapp D.J., et al. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 787 (1998) 181-190
28. Langsjo J.W., Kaisti K.K., Aalto S., et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99 (2003) 614-623
29. Langsjo J.W., Salmi E., Kaisti K.K., et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 100 (2004) 1065-1071
30. Sprenger T., Valet M., Woltmann R., et al. Imaging pain modulation by subanesthetic S-(+)-ketamine. Anesth Analg 103 (2006) 729-737
31. Brooks W.J., Petit T.L., and LeBoutillier J.C. Effect of chronic administration of NMDA antagonists on synaptic development. Synapse 26 (1997) 104-113
32. Hetman M., and Kharebava G. Survival signaling pathways activated by NMDA receptors. Curr Top Med Chem 6 (2006) 787-799
33. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 8 (2007) 621-632
34. Olney J.W., Labruyere J., Wang G., et al. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254 (1991) 1515-1518
35. Schrattenholz A., and Soskic V. NMDA receptors are not alone: dynamic regulation of NMDA receptor structure and function by neuregulins and transient cholesterol-rich membrane domains leads to disease-specific nuances of glutamate-signalling. Curr Top Med Chem 6 (2006) 663-686
36. Anis N.A., Berry S.C., Burton N.R., et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79 (1983) 565-575
37. MacDonald J.F., Bartlett M.C., Mody I., et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol 432 (1991) 483-508
38. Monaghan D.T., Bridges R.J., and Cotman C.W. The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Annu Rev Pharmacol Toxicol 29 (1989) 365-402
39. Orser B.A., Pennefather P.S., and MacDonald J.F. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 86 (1997) 903-917
40. Coates K.M., and Flood P. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol 134 (2001) 871-879
41. Seeman P., Ko F., and Tallerico T. Dopamine receptor contribution to the action of PCP. LSD and ketamine psychotomimetics. Mol Psychiatry 10 (2005) 877-883
42. Seeman P. Brain dopamine receptors. Pharmacol Rev 32 (1980) 229-313
43. Kapur S., and Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7 (2002) 837-844
44. Seeman P., and Kapur S. Anesthetics inhibit high-affinity states of dopamine D2 and other G-linked receptors. Synapse 50 (2003) 35-40
45. Roytblat L., Talmor D., Rachinsky M., et al. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth Analg 87 (1998) 266-271
46. Schmidt H., Ebeling D., Bauer H., et al. Ketamine attenuates endotoxin-induced leukocyte adherence in rat mesenteric venules. Crit Care Med 23 (1995) 2008-2014
47. Takenaka I., Ogata M., Koga K., et al. Ketamine suppresses endotoxin-induced tumor necrosis factor alpha production in mice. Anesthesiology 80 (1994) 402-408
48. Weiss M., Birkhahn A., Mettler S., et al. Stereoselective suppression of neutrophil function by ketamine?. Immunopharmacol Immunotoxicol 17 (1995) 91-107
49. Zilberstein G., Levy R., Rachinsky M., et al. Ketamine attenuates neutrophil activation after cardiopulmonary bypass. Anesth Analg 95 (2002) 531-536
50. Chen L.H., Liu L.X., Yang Y.J., et al. Neuroprotective effects of nimodipine and MK-801 on acute infectious brain edema induced by injection of pertussis bacilli to neocortex of rats. Chinese J Traumatol 6 (2003) 118-123
51. Engelhard K., Werner C., Eberspacher E., et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 96 (2003) 524-531
52. Proescholdt M., Heimann A., and Kempski O. Neuroprotection of S(+) ketamine isomer in global forebrain ischemia. Brain Res 904 (2001) 245-251
53. Kawasaki C., Kawasaki T., Ogata M., et al. Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood. Can J Anaesth 48 (2001) 819-823
54. Taniguchi T., Takemoto Y., Kanakura H., et al. The dose-related effects of ketamine on mortality and cytokine responses to endotoxin-induced shock in rats. Anesth Analg 97 (2003) 1769-1772
55. Sun J., Li F., Chen J., et al. Effect of ketamine on NF-kappa B activity and TNF-alpha production in endotoxin-treated rats. Ann Clin Lab Sci 34 (2004) 181-186
56. Sun J., Wang X.D., Liu H., et al. Ketamine suppresses intestinal NF-kappa B activation and proinflammatory cytokine in endotoxic rats. World J Gastroenterol 10 (2004) 1028-1031
57. Sun J., Wang X.D., Liu H., et al. Ketamine suppresses endotoxin-induced NF-kappaB activation and cytokines production in the intestine. Acta Anaesthesiol Scand 48 (2004) 317-321
58. Sun J., Zhou Z.Q., Lv R., et al. Ketamine inhibits LPS-induced calcium elevation and NF-kappa B activation in monocytes. Inflamm Res 53 (2004) 304-308
59. Winsauer G., and de Martin R. Resolution of inflammation: intracellular feedback loops in the endothelium. Thromb Haemost 97 (2007) 364-369
60. In: Motoyama E.K., and Davis P.J. (Eds). Smith's Anesthesia for Infants and Children. (ed 6) (1996), Mosby, St. Louis, MO
61. Schmitz M., and Ullah S. Right-sided obstructive leasions. In: Andropolous D.B., Stayer S.A., and Russell I.A. (Eds). Anesthesia for Congenital Heart Disease (2004), Futura Publishing, Philadelphia, PA
62. Green S.M., Denmark T.K., Cline J., et al. Ketamine sedation for pediatric critical care procedures. Pediatr Emerg Care 17 (2001) 244-248
63. Green S.M., and Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation in children. Ann Emerg Med 44 (2004) 460-471
64. Jobeir A., Galal M.O., Bulbul Z.R., et al. Use of low-dose ketamine and/or midazolam for pediatric cardiac catheterization. Pediatr Cardiol 24 (2003) 236-243
65. Mistry R.B., and Nahata M.C. Ketamine for conscious sedation in pediatric emergency care. Pharmacotherapy 25 (2005) 1104-1111
66. Vardi A., Salem Y., Padeh S., et al. Is propofol safe for procedural sedation in children. A prospective evaluation of propofol versus ketamine in pediatric critical care. Crit Care Med 30 (2002) 1231-1236
67. Hartvig P., Larsson E., and Joachimsson P.O. Postoperative analgesia and sedation following pediatric cardiac surgery using a constant infusion of ketamine. J Cardiothorac Vasc Anesth 7 (1993) 148-153
68. Tobias J.D., Martin L.D., and Wetzel R.C. Ketamine by continuous infusion for sedation in the pediatric intensive care unit. Crit Care Med 18 (1990) 819-821
69. Denmark T.K., Crane H.A., and Brown L. Ketamine to avoid mechanical ventilation in severe pediatric asthma. J Emerg Med 30 (2006) 163-166
70. Allen J.Y., and Macias C.G. The efficacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med 46 (2005) 43-50
71. Bell R.F., Dahl J.B., Moore R.A., et al. Peri-operative ketamine for acute post-operative pain: a quantitative and qualitative systematic review (Cochrane review). Acta Anaesthesiol Scand 49 (2005) 1405-1428
72. Elia N., and Tramer M.R. Ketamine and postoperative pain: a quantitative systematic review of randomised trials. Pain 113 (2005) 61-70
73. Humphries Y., Melson M., and Gore D. Superiority of oral ketamine as an analgesic and sedative for wound care procedures in the pediatric patient with burns. J Burn Care Rehabil 18 (1997) 34-36
74. Hocking G., and Cousins M.J. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 97 (2003) 1730-1739
75. Laufer M., Schippel P., Wild L., et al. [Treatment of extreme tumour pain with morphine and s-ketamine: a case report of an 11-year old girl.]. Schmerz 19 (2005) 220-224
76. Kronenberg R.H. Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal and intranasal administration. J Pain Palliat Care Pharmacother 16 (2002) 27-35
77. Church J., Zeman S., and Lodge D. The neuroprotective action of ketamine and MK-801 after transient cerebral ischemia in rats. Anesthesiology 69 (1988) 702-709
78. Marcoux F.W., Goodrich J.E., and Dominick M.A. Ketamine prevents ischemic neuronal injury. Brain Res 452 (1988) 329-335
79. Shapira Y., Artru A.A., and Lam A.M. Ketamine decreases cerebral infarct volume and improves neurological outcome following experimental head trauma in rats. J Neurosurg Anesthesiol 4 (1992) 231-240
80. Shapira Y., Lam A.M., Eng C.C., et al. Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury. Stroke 25 (1994) 1637-1643
81. Spandou E., Karkavelas G., Soubasi V., et al. Effect of ketamine on hypoxic-ischemic brain damage in newborn rats. Brain Res 819 (1999) 1-7
82. Anand K., Garg S., Rovnaghi C., et al. Ketamine reduces the cell death following inflammatory pain in newborn rat brain. Pediatr Res (2007) (epub ahead of print, Jun 25, 2007)
83. Bokesch P.M., Halpin D.P., Ranger W.R., et al. Immediate-early gene expression in ovine brain after hypothermic circulatory arrest: effects of aptiganel. Ann Thorac Surg 64 (1997) 1082-1087 discussion 1088
84. Bokesch P.M., Kapural M., Drummond-Webb J., et al. Neuroprotective, anesthetic, and cardiovascular effects of the NMDA antagonist. CNS 5161A, in isoflurane-anesthetized lambs. Anesthesiology 93 (2000) 202-208
85. Nagels W., Demeyere R., Van Hemelrijck J., et al. Evaluation of the neuroprotective effects of S(+)-ketamine during open-heart surgery. Anesth Analg 98 (2004) 1595-1603
86. Gahlinger P.M. Club drugs: MDMA, gamma-hydroxybutyrate (GHB). Rohypnol, and ketamine Am Fam Physician 69 (2004) 2619-2626
87. Narendran R., Frankle W.G., Keefe R., et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry 162 (2005) 2352-2359
88. Sherwin T.S., Green S.M., Khan A., et al. Does adjunctive midazolam reduce recovery agitation after ketamine sedation for pediatric procedures?. A randomized, double-blind, placebo-controlled trial. Ann Emerg Med 35 (2000) 229-238
89. Wathen J.E., Roback M.G., Mackenzie T., et al. Does midazolam alter the clinical effects of intravenous ketamine sedation in children?. A double-blind, randomized, controlled, emergency department trial. Ann Emerg Med 36 (2000) 579-588
90. Evans J., Rosen M., Weeks R.D., et al. Ketamine in neurosurgical procedures. Lancet 1 (1971) 40-41
91. Gibbs J.M. The effect of intravenous ketamine on cerebrospinal fluid pressure. Br J Anaesth 44 (1972) 1298-1302
92. Kaul H.L., Jayalaxmi T., Gode G.R., et al. Effect of ketamine on intracranial pressure in hydrocephalic children. Anaesthesia 31 (1976) 698-701
93. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
94. Ikonomidou C., Bosch F., Miksa M., et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
95. Scallet A.C., Schmued L.C., Slikker Jr. W., et al. Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci 81 (2004) 364-370
96. Slikker Jr. W., Paule M.G., Wright L.K., et al. Systems biology approaches for toxicology. J Appl Toxicol 27 (2007) 201-217
97. Slikker Jr. W., Zou X., Hotchkiss C.E., et al. Ketamine-induced neuronal cell death in the perinatal rhesus monkey. Toxicol Sci 98 1 (2007) 145-158